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INTRODUCTION 
Hyponatremia is a common electrolyte abnormality in cirrhosis of liver, 
as a result of high serum level of renin/aldosterone due to portal hypertension, 
a decreased vascular response to vasoactive drugs and reduced solute free water 
clearance. In patients with cirrhosis of liver, use of diuretics is one of the causes 
for hyponatremia.  
Hyponatremia has been associated with refractory ascites, spontaneous 
bacterial peritonitis and hepatic encephalopathy in patients with cirrhosis. 
Hyponatremia can be a key prognostic factor in patients with cirrhosis of liver 
when it is added to MELD score. Thus, hyponatremia could be useful in 
predicting prognosis & development of complications in cirrhotic patients. 
There is a lot of research in the field of cirrhosis and its various 
complications. Various studies are currently assessing the role of hyponatremia 
as an independent risk factor for complications of cirrhosis and its possible 
implication in prevention. This study will prognosticate the role of 
hyponatremia in cirrhosis of liver. 
MELD-Na score differs from the standard MELD score because it uses 
the Na value to adapt the result and to provide a more specialized view and 
improves upon the MELD Score for liver cirrhosis, especially in regard to the 
mortality prediction. 
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Serum sodium is often used as a marker for the severity of a disease, 
especially in cirrhosis where hyponatremia indicates solute free water retention 
and the indirect marker of portal hypertension during cirrhosis. 
Hyponatremia is in general considered a predictor of early mortality, 
therefore independent of the previous MELD score but now more specific and 
superior to the original model for patients awaiting transplant. 
Candidates who are at least 12 years old receive an initial MELD score 
equal to: 
MELD = 0.957 × ln(Cr) + 0.378 × ln(bilirubin) + 1.120 × ln(INR) + 0.643 
Then, round to the tenth decimal place and multiply by 10. Maximum 
MELD = 40. Then MELD Na score is calculated for each patient.  
     MELD Na = MELD − Na − [0.025 × MELD × (140 − Na)] + 140 
Survival chances change significantly, especially in the ranges of sodium 
change between 120 and 135mEq/L, when a decrease in serum sodium of one 
unit corresponds to a 12% increase in mortality risk in the following 3 months. 
MELD Na interpretation 
The MELD models are basically a severity index by the United Network 
for Organ Sharing (UNOS) that allows a prioritization of organ transplant by 
showing the mortality risk in severe cirrhosis cases. The commonly met score 
range is usually between 6 and 40 but extremes can become apparent. The 3 
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month mortality prediction as per the MELD definition in regard to waiting list 
mortality is listed below: 
 MELD score >40: 71.3% mortality. 
 MELD score 30–39: 52.6% mortality. 
 MELD score 20–29: 19.6% mortality. 
 MELD score 10–19: 6.0% mortality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND 
OBJECTIVES 
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AIMS AND OBJECTIVES 
 
1. To study the prevalence of hyponatremia in cirrhosis liver and  
2. To show that MELD- SODIUM score is a better predictor of mortality than 
standard MELD score among end stage liver disease patients who are 
awaiting liver transplantation. 
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REVIEW OF LITERATURE 
 
Cirrhosis is defined histologically as a diffuse hepatic process characterized 
by fibrosis and the conversion of normal liver architecture into structurally 
abnormal nodules. The progression of liver injury to cirrhosis may occur over 
weeks to years.  
Cirrhosis is an irreversible liver disease with definable pathological change 
and a spectrum of clinical features.(1) The hallmark pathological events are 
1.chronic damage of the hepatocytes which is not reversible 2.fibrosis of the liver 
distorting the architecture 3.reactive nodular regeneration  
Cirrhosis is defined “anatomically as a diffuse process with fibrosis and 
nodule formation”. The hallmark pathological feature chronic extreme damage to 
the hepatocyte followed by replacement of normal liver tissue by fibrosis which is 
extensive with nodule formation. This is mainly due to necrosis of hepatocytes, loss 
of reticular network &regeneration of remaining liver tissue by nodules. whatever 
may be etiology the end result is the same. (2) 
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CAUSES OF CIRRHOSIS 
In Developed countries the prevalence of alcoholic cirrhosis, NASH 
cirrhosis (non - alcoholic steatohepatitis) and viral cirrhosis, in particular hepatitis 
C, are all growing. In developing countries, the major causes are hepatitis virus B 
and C, but alcohol and autoimmune conditions are also at increase. (3)  Various 
causes of cirrhosis are: 
1. Alcoholism  
2. Chronic viral hepatitis(hepatitis B and C)    
3. Autoimmune hepatitis 
4. NASH (non-alcoholic steatohepatitis)  
5. Biliary cirrhosis (primary biliary cirrhosis, primary sclerosing 
cholangitis, autoimmune cholangiopathy)  
6. Cardiac cirrhosis   
7. Inherited metabolic liver disease (hemochromatosis, wilsons disease, 
alpha 1 antitrypsin deficiency,)  
8. Cryptogenic cirrhosis 
Some patients have more than one cause for cirrhosis (such as alcohol excess 
and viral hepatitis). A large portion of patients (up to 20%) do not have an 
recognizable cause for cirrhosis and are named as cryptogenic cirrhosis 
MORPHOLOGICAL CLASSIFICATION: 
It can classified based on the nodular size. 
Nodules <3mm are said to be micronodular and >3mm as macronodular 
1. Micronodular or Laennec”s cirrhosis 
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2. Macronodular cirrhosis 
3. Mixed type 
PATHOGENESIS 
Induction of fibrosis occurs with activation of hepatic stellate cells to 
myofibroblasts resulting in the development of increased amounts of collagen and 
other components of the extracellular matrix leading to architectural distortion 
inturn resulting in decrease in function and mass. 
 
CLINICAL FEATURES 
Patients may present for the first time with the complications of cirrhosis or 
may be asymptomatic and incidentally be identified during checkup for unrelated 
causes or because of abnormal liver tests. 
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In clinical terms., cirrhosis is classified in to 
 “ Compensated form” and 
 “Decompensated form”, 
Decompensation is characterized by cirrhosis complicated by one or more 
following features like - jaundice, ascites, hepatic encephalopathy, bleeding 
varices. Ascites is usually the first sign of decompensation, whereas these features 
and any complication secondary to Portal hypertension is absent in compensated 
cirrhosis. This discrepancy clinically is very important because of the implication 
it has in the prognostication and treatment. Compensated cirrhosis patients have a 
ten year survival rate of 50% whereas decompensated patients have a survival rate 
of about 50% in 18 months. A decompensated patient may become compensated 
when the inciting cause or the triggering cause is removed and thereby the prognosis 
may improve. Patients who have developed complications of their liver disease and 
have become decompensated should be considered for liver transplantation. 
COMPENSATED CIRRHOSIS: 
At this stage the cirrhotic process of the liver is not severe enough to alter 
the function considerably and so the patients may be asymptomatic or present with 
non-localizing manifestations or may be picked incidentally due to alteration in 
biochemical parameters or imaging studies Patients may have fatigue, anorexia, 
weight loss, flatulence, dyspepsia, abdominal pain. (4) 
 On examination palmar  erythema,  pedal  edema,  spider  naevi,  may  point  
towards  cirrhosis. Abdominal examination may reveal an epigastric mass which is 
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the enlarged left lobe of the liver and splenomegaly. Biochemical tests are usually 
within normal limits in this group. The most common LFT abnormality in this 
group include mildly elevated transaminases, or GGT. 
Confirmation is by liver imaging or liver biopsy. Factors like bacterial 
infection, trauma, or medications, surgery may precipitate decompensation in a 
compensated cirrhosis. 
DECOMPENSATED CIRRHOSIS: 
These patients present with ascites, jaundice, altered sensorium,bIeeding 
manifestations. 
SYMPTOMS: 
Presentation in these patients may be with features of jaundice, pedal edema, 
abdominal distension, pruritis. Upper GI bleed most commonly result in malena, 
hematemesis. Altered sensorium ranging from sleep disturbances to florid 
confusion and coma because of hepatic encephalopathy. In women, menstrual 
irregularities are common due to anovulation. Men, may manifest hypogonadism 
in the form of impotence, loss of sexual drive, testicular atrophy and infertility. (5) 
“Portal hypertension is an important complicating feature of decompensated 
cirrhosis and is responsible for the development of ascites and bleeding from 
esophagogastric varices which  makes cirrhosis decompensated” . 
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GENERAL EXAMINATION: 
Decreasing blood pressure - with progression of cirrhosis, mean arterial 
pressure often decreases. Hypertensive patients may become normotensive. 
Patients can have mild fever (37.5 -38*C). This is probably because of 
bacteremia due to gram negative organisms.Ongoing hepatocyte necrosis and 
development of hepatocellular carcinoma may also contribute. 
Jaundice (This happens once the functional impairment due to hepatocyte 
destruction has exceeded the process of regeneration. The deeper the jaundice, more 
severe is hepatic decompensation) 
Skin findings: 
Bronze piginentation of the skin may throw light on the etiology as it occurs 
in hemochromatosis. 
Presence of  "vascular  spiders” (arterial spiders/spider naevi / spider  
telengiectasia spider angioma),  They are seen in distribution of venous drainage 
areas of superior vena cava. As liver function worsens, new spiders may appear. 
They are more frequently associated with alcoholic cirrhosis. They occur normally 
in pregnancy and in some normal individuals.”Hepatopulmonary” syndrome is 
characterized by multiple spiders and clubbing. 
“Palmar erythema”: palms are warm and red in colour especially over the 
thenar eminence,hypothenar eminence and the pulp of the fingers.  
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Mechanism of both arterial spiders and palmar erythema may be due to 
estrogen excess. The estrogens are inactivated in the liver. Serum estradiol level is 
normal and serum free testosterone is reduced. Thus the high estradiol /Free 
testosterone ratio may he attributed to these findings. 
“Leukonychia”  may be related to hypoalbuminemia. 
“Clubbing” can occur pan digitally especially with development of hepato 
pulmonary syndrome or in cystic fibrosis.”Hypertrophic osteoarthropathy” has also 
been observed. 
“Dupuytrens contracture” may be present.This is characterized by thickened 
palmar fascia resulting from unorganized proliferation of the fibroblasts. 
Head and neck findings- 
Parotid enlargement, alopecia, fetor hepaticus, KF ring in the eyes due to 
Wilson's disease may be present. 
“Fetor hepaticus” refers to the breath of the cirrhosis patients that has a sweet 
pungent nature. This is because of presence of mercaptans. 
Chest findings – 
“Gynecomastia” in males may be seen along with other features of 
feminization like change in the male pattern of pubic hair, loss of axillary hair and 
chest hair. It is because the androstenedione that is synthesized by the adrenals gets 
aromatized in to estrone and finally in to estradiol in the adipose tissue. 
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Abdominal findings- 
Abdominal examination may reveal the presence of ascites, hepatomegaly, 
splenomegaly, and dilated abdominal wall veins. 
“Ascites” — Ascites refers to excessive collection of peritoneal fluid. In 
massive ascites fluid thrill may be present where as in moderate ascites shifting 
dullness is to be elicited.If flanks are full it is probably due to ascites and not fat. 
“Hepatomegaly” -The cirrhotic liver may be enlarged, shrunken or normal 
sized. On palpation, consistency is firm and nodular. Features such as shape, 
consistency are to be better appreciated on palpation as the estimation of liver size 
correlates less accurately with imaging studies. Presence of a palpable liver in 
cirrhosis usually signifies alcoholic liver disease, primary biliary cirrhosis, 
hemochromatosis, transformation into hepatocellular carcinoma, Budd Chiari 
syndrome. 
“Splenomegaly”- Splenomegaly in cirrhosis is due to congestion resulting 
from portal hypertension.however, correlation between splenic size and portal 
pressure is poor- implicating that there  may be other factors contributing. 
“Caput medusae” - With the development of portal hypertension, the portal 
venous blood gets carried through the periumbilical veins in to the umbilical vein 
which becomes patent in cirrhosis ,from there the blood drains in to the upper and 
lower abdominal veins that end up in the systemic circulation .These veins become 
engorged and prominent. Thus the portal blood gets shunted to systemic circulation. 
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This appearance resembles the head (Caput) of the mythical Gorgon Medusa thus 
termed caput medusae. 
Dilated abdominal veins developing in SVC obstruction and IVC obstruction 
should be differentiated from dilated veins due to cirrhosis. In order to distinguish 
the cause of obstruction direction of flow is to be assessed. In IVC obstruction the 
flow is below upwards whereas in cirrhosis the flow of the blood is away from the 
cause of obstruction direction or flow is to be assessed. In IVC obstruction the flow 
is below upwards. However since these veins in both conditions may lack valves, 
the flow may be bidirectional and the test may be misleading. Moreover the dilated 
veins due to obstruction are more commonly seen in the back and loin. 
“Peptic ulcers” occur in 11% of cirrhosis patients. Duodenal ulcers are more 
frequently encountered than gastric ulcers. Colonization by helicobacter pylori is 
higher in cirrhosis when compared to normal population. Abdominal hernias are 
more common in patients with ascites. They should be repaired only if severe 
enough to cause mortality in alcoholics. Associated chronic pancreatitis can be 
present which may relapse, so this should be considered a differential diagnosis in 
alcoholic cirrhosis patients presenting with abdominal pain. 
Neurological findings - The presence of Asterixis or liver flap indicate the presence 
of hepatic encephalopathy. 
Genitourinary findings-   Testicular atrophy in males. 
Endocrine changes- Hyperglycemia occurs in about 80% of cirrhotic patients in 
the form of glucose intolerance. Only around 10-20% are truly diabetic. 
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INVESTIGATIONS: 
LIVER FUNCTION TEST ABNORMALITIES- 
“Aminotransferases” - In chronic hepatitis ALT is increased more than AST 
.As hepatitis progresses to cirrhosis ,AST becomes more elevated than ALT and 
thus the ratio of AST to ALT is reversed from <I to greater than 1.In cirrhosis 
patients the enzymes can be within normal values or may become moderately 
elevated. 
  “Alkaline phosphatase” - Alkaline phosphatase enzyme is elevated 2 to 3 
times normal in cirrhosis. If elevated more than that, primary biliary cirrhosis or 
sclerosing cholangitis should be considered as the etiology. 
 “Gammaglutamyl transpeptidase” - Levels of GGT and alkaline 
phosphatase are usually proportionately elevated.Disproportionately high levels of 
GGT will be seen in alcoholic liver discease.GGT present in the rnicrosomes gets  
induced due to alcohol intake. 
“Bilirubin” - In compensated stage of cirrhosis, the bilirubin levels are 
usually normal. Decompensation is characterized by increasing levels of bilirubin  
and it is one of the prognostic indicators used in Child Pugh score.  
“Albumin” - Albumin is exclusively synthesised in the liver. With worsening  
cirrhosis, due to the decline in the synthetic function of the liver. Albumin levels 
also fail.It is also one of the prognostic indicators for survival in child pugh scoring 
system. 
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“Prothrombin time” -Many of the coagulation factors are synthesized in 
liver. Prothrombin time which measures the extrinsic coagulation pathway, is a 
marker for the synthetic function of the liver. Thus coagulopathy worsens as 
cirrhosis progresses. 
Serum electrolytes – “hyponatremia” can occur in patients with ascites. 
Severity can be correlated with worsening cirrhosis. 
Hematologic abnormalities-Thrornbocytopenia, anemia and lencopenia can 
occur. The earliest abnormality to occur is thrombocytopenia and it is a marker for 
the development of portal hypertension. “Pancytopenia” can even be the presenting 
feature in asymptomatic compensated cirrhosis. This is due to sequestration of the 
cells in the enlarged spleen. Platelet count usually does not fall below 50,000.This 
does not per se cause bleeding but bleeding can get aggravated in the presence of 
coagulopathy. 
“Anemia” in cirrhosis is mainly because of upper G1 bleed. Anemia can also 
be present as a result of direct suppression of bone marrow by alcohol,splenic 
sequestration and hemolysis, folate deficiency. 
Other abnormalities - In cirrhosis, the globulin levels are high. This is 
because of shunting of bacterial antigens in the portal venous blood which are 
normally filtered by the liver in to systemic circulation leading which induces 
production of immunoglobulins. Marked elevations of IgG may point towards the 
presence of autoimmune hepatitis. 
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Imaging studies: 
  Cirrhosis can be diagnosed radiologically using ultrasound, portal vein 
Doppler, CT and MRI in specific cases. 
 Ultrasonography - Ultrasonography is a non-invasive routinely used 
investigation to diagnose cirrhosis. The size of the liver, the nodularity, 
the portal vein diameter, presence of ascites and splenomegaly can be 
assessed. Doppler studies to check the direction of blood flow in the 
portal vein aids in the diagnosis of portal hypertension. Presence HCC 
and portal vein thrombosis can also be made out. 
 CT is not the first choice in the diagnosis of cirrhosis. It may be useful 
when investigating  liver  malignancy  or  secondaries  or  pancreatic 
pathology. 
 MRI may be useful in hermochromatosis to reveal iron overload. MRA 
can determine  portal vein flow and dynamics. 
 Elastography to assess the stiffness of the liver tissue is also available. 
Liver biopsy: 
The gold standard investigation for diagnosing cirrhosis is liver biopsy 
Nowadays liver biopsy is rarely required to diagnose cirrhosis. Only  certain  
situations  may  require  performing  liver  biopsy  such  as  for demonstrating the 
underlying metabolic cause of cirrhosis such as NASH, Wilson disease, 
hemochromatosis, and alpha 1 antitrypsin deficiency. 
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MAJOR COMPLICATIONS OF CIRRHOSIS: 
With the progression of cirrhosis and development of portal hypertension, 
various complications occur as a result of either the decreased synthetic, excretory, 
metabolic functions of the liver and also some secondary to portal hypertension. (6)  
The various complications include: 
 
PORTAL HYPERTENSION: 
Portal hypertension is defined as the elevation of the hepatic venous pressure 
gradient (HVPG) >5 mmHg. 
Portal hypertension occurs as a result of two processes happening simultaneously: 
1. The altered architecture of the liver due to fibrosis and regenerating nodules,  
results in increased resistance to the flow of portal blood. 
2. Increased blood flow secondary to splanchnic vasodilatation. 
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This portal hypertension results in variceal bleeding and ascites. The causes 
of portal hypertension are divided into pre-hepatic, post hepatic and intra-hepatic 
causes.  
Pre-hepatic causes are thrombosis of portal vein and splenic vein thrombosis 
which results in development of sinistral hypertension or left sided portal 
hypertension. Portal  vein  thrombosis can  occur secondary to cirrhosis  per se, 
pancreatitis, abdominal trauma, infection or hematological causes such as essential 
thrombocytosis, polycythemia vera, protein C and S deficiency. (7-10) 
  Post hepatic causes are those affecting the hepatic veins and venous drainage 
in to the heart. Conditions include Budd Chiari syndrome, veno occlusive  disease,  
constrictive  pericarditis,  chronic  right  sided  congestion, restrictive 
cardiomyopathy. Intra-hepatic causes include pre-sinusoidal causes such as 
schistosomiasis, congenital portal fibrosis and post sinusoidal causes including 
veno-occlusive disease and cirrhosis causes sinusoidal form of portal hypertension. 
Clinically significant  portal  hypertension  occurs  in  around 60% of 
cirrhosis patients.  The primary complications of portal hypertension include 
ascites, bleeding varices  splenomegaly, hypersplenism etc. Splenomegaly  results  
from  congestion  due  to  increased  portal  pressure. Hypersplenism with  
development  of  thrombocytopenia  may  be  the  first presentation of portal 
hypertension even before ascites may develop. 
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PATHOPHYSIOLOGY: 
“Portal hypertension” results due to increased intrahepatic resistance and 
increased portal blood flow. As there is increased hepatic resistance, hepatic 
compliance decreases. Increase in portal pressure causes small changes in blood 
flow. A normal liver can adapt to it. But it can have a prominent stimulatory effect 
on portal pressure in the cirrhotic liver. 
Due to hyperdynamic state there is an increase in portal venous inflow. The 
Collateral vessels get dilated and new vessels sprouts. There is an increase in flow 
from high pressure portal veins to low pressure systemic veins. This process of 
angiogenesis and collateral vessel formation can cause esophageal varices. These 
changes in portal flow and resistance are mainly originating from mechanical and 
vascular factors. 
“Mechanical factors” include the fibrosis and nodularity of the cirrhotic 
liver, with distortion of the vascular architecture and the remodeling that  occur in 
the systemic and splanchnic vascular systems in response to the chronic increases 
in flow and shear stress that characterize the “hyperdynamic circulatory state”.  
“Vascular factors” include intrahepatic vasoconstriction, which contributes 
to increased intrahepatic resistance, and the splanchnic and systemic vasodilatation 
that accompanies the hyperdynamic circulatory state.This increase in hepatic 
vascular resistance is mainly contributed by decrease in the production of the 
“vasodilator NO” and an increase in the production of the “vasoconstrictor ET-1”. 
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Other vasoactive mediators, like cysteinyl leukotrienes, thromboxane, 
angiotensin, and hydrogen sulfide, have also been implicated in the development of 
increased intrahepatic resistance in cirrhosis. 
The “hyperdynamic circulation” is characterized by peripheral and 
splanchnic vasodilatation,reduced mean arterial pressure, and increased cardiac 
output. Vasodilatation, particularly in the splanchnic bed, permits an increase in 
inflow of systemic blood into the portal circulation.Splanchnic vasodilatation is 
caused in large part by relaxation of splanchnic arterioles and ensuing splanchnic 
hyperemia. 
Studies of experimental portal hypertension have demonstrated that 
splanchnic vascular endothelial cells are primarily responsible for mediating 
splanchnic vasodilatation and enhanced portal venous inflow through excess 
generation of NO. This excess generation of NO and ensuing 
vasodilatation,hyperdynamic circulation, and hyperemia in the splanchnic and 
systemic circulation contrasts with the hepatic circulation, in which NO deficiency 
contributes to increased  intrahepatic resistance.The vascular factors that contribute 
to portal hypertension are particularly important because they are reversible and 
dynamic and therefore compelling targets for experimental therapies. 
One third of the patients with cirrhosis have gastric and oesophageal varices, 
Thus it has become mandatory to screen all patients with established cirrhosis for 
the presence of varices using upper GI endoscopy. The risk of variceal bleed 
depends on several factors like the varices size, severity of cirrhosis, tense ascites, 
and increased wedged hepatic vein pressure. In patients with liver cirrhosis the 
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development of portal hypertension may be revealed by the presence of 
thrombocytopenia, appearance of an enlarged spleen, encephalopathy, development 
of ascites and esophageal varices with or without bleeding. CT or MRI abdomen 
can be performed in doubtful cases or interventional radiological procedure to 
determine the free and wedged hepatic vein pressure and the gradient between the 
two can be found out. It is normally 5 mm Hg and if more than 12 mm Hg it signifies 
increased risk of bleeding. Once bleeding occurs acute therapy is to arrest the bleed 
and then followed by prophylaxis against repeated bleeding. Acute management is 
with intravenous fluids and blood products and use of octreotide at a rate of 50-100 
mic/hour. This is followed by endoscopic variceal band ligation till the varices are 
obliterated. Non selective beta-blockers can be used as medical prophylaxis. If  this 
mode of management fails, TIPS can be tried. 
 
GASTROESOPHAGEAL VARICES: 
Varices are dilated and tortous veins that develop commonly within the 
oesophagus and stomach of patients with cirrhosis. They are Porto-systemic 
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collaterals – i.e. vascular channels that link the portal venous and the systemic 
venous circulation and develop as a result of portal hypertension (a dreaded 
complication of cirrhosis), preferentially in the submucosa of the lower esophagus 
and also in stomach. (11-12) 
 Other Sites of portal collaterals: 
1. Oesophageal and gastric varices 
2. Hemorrhoids. 
3. Caput medusae. 
4. Retroperitoneal sites 
 Rupture and bleeding from esophageal varices  are associated with a high 
mortality rate. Despite improved diagnosis and treatment for variceal hemorrhage, 
the mortality rate still remains high (20%-35%). Variceal bleeding contributes to 
10–30% of all cases of UGI bleeding. 
A cirrhosis patient with no varices has not yet developed portal hypertension, 
or his or her portal pressure is not yet high enough for varices to develop. As portal 
pressure increases, small varices start to develop. With time, as circulation 
increases, blood flow through the varies will increase, leading to formation of  large 
varices. When the expanding force exceeds the maximal wall tension, rupture of 
varices occur resulting in hemetemesis. Thus we need to modify  the tension of the 
wall with drugs and other measures, to prevent recurrence. 
EPIDEMIOLOGY 
Most common location is distal oesophagus, but varices may occur in 
anywhere along the gastrointestinal tract. Around 50% of patients with cirrhosis 
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may develop gastroesophageal varices. Gastric varices are present in 5–33% of 
patients with portal hypertension. The frequency of esophageal varices varies from 
30% to 70% in patients with Cirrhosis and 9–36% of patients have what are known 
as “high-risk” varices.  
Annual rate of development  of varices  in patients with cirrhosis is around 
5–8%, but the varices are large enough to pose a risk of bleeding in only 1–2% of 
cases. Around 4–30% of patients with small varices will go on to develop large 
varices each year and will therefore be at risk of bleeding. Variceal hemorrhage 
occurs at a yearly rate of 5-15%, and 6-week mortality after variceal hemorrhage is 
about 20%. In general, variceal bleeding ceases spontaneously in 40-50% of 
patients, but incidence of early re bleeding ranges between 30% and 40% within 
first 6 weeks, and about 40% of all re bleeding episodes occur within the first 5 
days.  
Gastric varices (GV) bleed less frequently than esophageal varices and are 
responsible for 10-30% of all variceal hemorrhages. However, gastric variceal 
bleeding tends to be more severe with higher mortality. In addition, a high 
proportion of patients, around 35-90%, rebleed after spontaneous hemostasis. The 
presence of gastroesophageal varices correlates with the severity of liver disease. 
The severity of cirrhosis can be scored using the Child–Pugh classification 
system.40% of Child–Pugh A patients and 85% of Child–Pugh C patients can have 
varices. 
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PATHOPHYSIOLOGY: 
Four distinct zones of venous drainage at the gastroesophageal junction are 
particularly relevant to the formation of esophageal varices. The “gastric zone”, 
which extends for 2 to 3 cm below the gastroesophageal junction, comprises veins 
that are longitudinal and located in the submucosa and lamina propria. They come 
together at the upper end of the cardia of the stomach and drain into short gastric 
and left gastric veins. The “palisade zone” extends 2 to 3 cm proximal to the gastric 
zone into the lower esophagus. Veins in this zone run longitudinally and in parallel 
in 4 groups corresponding to the esophageal mucosal folds. These veins anastomose 
with veins in the lamina propria. The perforating veins in the palisade zone do not 
communicate with extrinsic (periesophageal) veins in the distal esophagus, hence 
more chance of bleeding. The palisade zone is the dominant watershed area between 
the portal and systemic circulations. More proximal to the palisade zone in the 
esophagus is the “perforating zone”, where there is a network of veins. These veins 
are less likely to be longitudinal and are termed “perforating veins” because they 
connect the veins in the esophageal submucosa and the external veins. The “truncal 
zone”, the longest zone, is approximately 10 cm in length, located proximal to the 
perforating zone in the esophagus, and usually characterized by 4 longitudinal veins 
in the lamina propria and they are unlikely to bleed. The periesophageal veins drain 
into the azygos system, and as a result, an increase in azygos blood flow is a 
hallmark of portal hypertension. The venous drainage of the lower end of the 
esophagus is through the coronary vein, which also drains the cardia of the stomach, 
into the portal vein. 
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The fundus of the stomach drains through short gastric veins into the splenic 
vein. In the presence of portal hypertension, varices may therefore form in the 
fundus of the stomach. Splenic vein thrombosis usually results in isolated “gastric 
fundal varices”. Because of the proximity of the splenic vein to the renal vein, 
spontaneous splenorenal shunts may develop and are more common in patients with 
gastric varices than in those with esophageal varices. 
TREATMENT 
  It includes primary prophylaxis and prevention of re bleeding. 
Non selective beta blockers or endoscopic variceal band ligation are required 
as primary prophylaxis for varices that are at increased risk of bleeding. 
Management of acute bleeding includes vasoconstricting agents like octreotide, 
vasopressin. Sengstaken-blakemore tube or Minnesota tube are used for patients 
not immediately accessible for endoscopic ligation. Best line of management is 
endoscopic ligation of bleeding varices. TIPS should be reserved for patients who 
fail endoscopic or medical treatment or who are poor surgical risks and as an bridge 
to transplantation. 
ASCITES 
Ascites is defined as the accumulation of fluid within the peritoneal cavity. 
The most common cause of ascites is portal hypertension. An increase in 
intrahepatic resistance leads to increased portal pressure. Presence of splanchnic 
vasodilation which lead to increased portal flow also leads to formation of ascites. 
These hemodynamic changes results in sodium retention and activation o renin 
angiotensin aldosterone mechanism which further leads to ascites. Other factors like 
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hypoalbuminea leads to ascites. Patient presents with increased abdominal 
distension and peripheral edema. If ascetis is massive , patient may also develop 
hepatic hydrothorax. Diagnosis is done by physical examination and imaging. 
 
A diagnostic paracentesis should be done. SAAG ratio should be calculated 
to identify the cause of ascites, whether due to portal hypertension or not. SAAG > 
1.1 g/dl indicates increased portal pressure. Treatment includes salt restricted diet 
< 2g/day, spironolactone 100-200 mg/d initially and furosemide 40-80 mg/d and 
then titrated. patients with refractory ascites should undergo repeated large volume 
paracentesis. (13-16) 
HEPATORENAL SYNDROME 
It is a type of functional renal failure in the absence of intrinsic kidney 
disease which occurs in 10% of decompensated liver disease patients. This is due 
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to marked imbalance in arterial renal circulation, the mechanism of which is poorly 
understood. There are two types of HRS  
1. Type 1 HRS – a progressive impairment in renal function and a significant 
reduction in creatinine clearance within 1-2 weeks of presentation 
2. Type 2 HRS – a reduction in glomerular filtration rate with an elevation of 
serum creatinine level in progressive manner and has a better outcome. 
The best treatment of HRS is liver transplantation. Others drug useful in 
renal vasodilation are Dopamine or prostaglandin analogues. Currently, midodrine, 
octreotide, intravenous albumin are tried. (17) 
HEPATIC ENCEPHALOPATHY 
It is defined as the “alteration in the mental status and cognitive function 
occurring in the presence of liver failure”. Gut derived neurotoxins, especially 
ammonia is elevated. other compounds like false neurotransmitters and mercaptans 
are also implicated in the pathogenesis of hepatic encephalopathy. 
The symptoms of hepatic encephalopathy may range from mild to severe 
and may be observed in as many as 70% of patients with cirrhosis. Symptoms are 
graded on the following scale (WEST HAVEN GRADING):  
 Grade 0 - Subclinical; normal mental status but minimal changes in 
memory, concentration, intellectual function, coordination  
 Grade 1 - Mild confusion, euphoria or depression, decreased attention, 
slowing of ability to perform mental tasks, irritability, disorder of sleep 
pattern (ie, inverted sleep cycle)  
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 Grade 2 - Drowsiness, lethargy, gross deficits in ability to perform 
mental tasks, obvious personality changes, inappropriate behavior, 
intermittent disorientation (usually with regard to time)  
 Grade 3 - Somnolent, but arousable state; inability to perform mental 
tasks; disorientation with regard to time and place; marked confusion; 
amnesia; occasional fits of rage; speech is present but incomprehensible  
 Grade 4 - Coma, with or without response to painful stimuli.  
Findings on physical examination in hepatic encephalopathy include 
asterixis. Treatment includes hydration and correction of electrolyte imbalance and 
avoidance of animal proteins. The mainstay of treatment is lactulose. Rifaximin 
550mg bd has been effective in the treatment. Zinc supplementation is also found 
to be useful. (18-20) 
SPONTANEOUS BACTERIAL PERITONITIS 
It is characterized by “spontaneous infection of the ascetic fluid without an 
intra abdominal source”. Bacterial translocation is the presumed mechanism. The 
most common organism complicating is E.coli, however organisms like 
streptococcus viridans, staph. Aureus, and enterococcus are identified. Presence of 
absolute neutrophil count > 250/microL in ascitic fluid makes the diagnosis. Second 
generation cephalosporins, especially cefotaxime is used in the treatment. (21-24) 
SODIUM AND WATER - COMPOSITION OF BODY FLUIDS 
Water is the most abundant constituent in the body, comprising 
approximately 60 percent of body weight in men and 50 percent in women. This 
difference is attributable to differences in the relative proportions of adipose tissue 
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in men and women. Total body water is distributed in two major compartments - 
55 to 75 percent is “intracellular”   [ intracellular fluid ICF) ] and 25 to 45 percent 
is “extracellular” [ extracellular fluid (ECF) ]. The ECF is further subdivided into 
intravascular (plasma water) and extravascular (interstitial) spaces in a ratio of 1 :3. 
The solute or particle concentration of a fluid is known as its osmolality and 
is expressed as milliosmoles per kilogram of water (mosmol /kg). Water crosses 
cell membranes to achieve osmotic equilibrium (ECF osmolality =ICF osmolality). 
The extracellular and intracellular solutes or osmoles are markedly different due to 
disparities in permeability, and the presence of transporters and active pumps. The 
major ECF particles are Na+ and its accompanying anions Cl- and HCO3, where as 
K+ and organic phosphate esters (ATP, creatine phosphate, and phospholipids) are 
the predominant ICF osmoles. Solutes that are restricted to the ECF or the ICF 
determine the effective osmolality (or tonicity) of that Compartment. Since Na+ is 
largely restricted to the extracellular compartment, total body Na+ content is a 
reflection of ECF volume. 
Likewise, K+ and its attendent anions are predominantly limited to the lCF 
and are necessary for normal cell function. Therefore, the number of intracellular 
particles is relatively constant, and a change in ICF osmolality is usually due to a 
change in ICF water content. However, in certain situations, brain cells can vary 
the number of intracellular solutes in order to defend against large water shifts. This 
process of osmotic adoption is important in the defence of cell volume and occurs 
in chronic hyponatraemia and hypernatremia. This response is mediated initially by 
transcellular shifts of K+ and Na+, followed by synthesis, import, or export of 
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organic solutes (so- called osmolytes) such as inostial, betaine, and glutamine. 
During chronic hyponatraemia, brain cells lose solutes, thereby defending cell 
volume diminishing neurologic symptoms. The converse occurs during chronic 
hypernatremia . Certain solutes, such as urea, do not contribute to water shift across 
cell membranes and are known as ineffective osmoles. 
“Fluid movement” between the intravascular and interstitial spaces occurs 
across the capillary wall and is determined by the Starling Transcapillary hydraulic 
pressure gradient exceeds the corresponding oncotic pressure gradient, thereby 
favouring the movement of plasma ultrafiltrate into the extravascular space. The 
return of fluid into the intravascular compartment occurs via lymphatic flow. (26) 
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Sodium and its Functions 
Body involvement                               Functions 
 
Neuromuscular              Transmission and conduction of nerve impulses 
                                            (Sodium pump-see cellular) 
Body fluids                          Largely responsible for the osmolality of vascular 
f'luids. Doubling Na level gives the approximate     
serum osmolality. 
Regulation of body fluid (increased sodium levels   
cause water retention ) 
Cellular                               Sodium pump action. Sodium shifts into cells as 
Potassium shifts out of the cells, repeatedly, to 
Maintain water balance and neuromuscular activity.       
When Na shifts into the cell, depolarization occurs      
and when Na shifts out of the cell, K shifts back into 
the cell, and repolarization occurs. 
                                             Enzyme activity. 
Acid-base levels                Assist with the regularization of acid-base balance. 
Sodium combines readily with chloride (Cl) or 
Bicarbonate (HCO3) to regulate the acid-base balance. 
HYPONATREMIA 
Hyponatremia is defined as “a plasma sodium concentration ([Na]) less than 
135 Mm”, is a very common disorder. This disorder is alost always the result of an 
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increase in circulating AVP and /or increased renal sensitivity to AVP, combined 
with intake of free water. A notable exception is hyponatremia due to low solute 
intake.  
Severe symptomatic hyponatremia can be associated with permanent brain 
damage or death. The importance of recognition and evaluation of this condition 
lies not only in the consequences of hyponatremia but also in its management.                
(27-28) 
The commonest causes of hyponatremia are acute water overload in post-
operative patients, drugs (including diuretics), and them Syndrome of inappropriate 
secretion of antidiuretic hormone (SIADH). 
 
CAUSES OF HYPONATREMIA 
I.PSEUDOHYPONATREMIA 
A. Normal plasma osmolality 
 Hyperlipidemia 
 Hyperproteinemia 
 Post transurethral resection of prostate/ bladder tumour 
33 
 
B. Increased plasma osmolality with hyponatremia 
 Hyperglycemia  
 Mannitol  
ARTIFACTUAL OR SPURIOUS 
Lab reporting error secondary to: 
Hyperglycemia. Correct Sodium (each increase of blood glucose 
of 100 mgldl decreases serum sodium by 1.7 mEq/L). 
Hyperlipidemia. Measured serum osmolality will be normal and 
greater than the calculated osmolality 
(Osm = [2 x Na] + [ Glucose / 18] + [ BUN/2.8]}. 
TYPES OF HYPONATREMIA 
Dilutional/ Hypervolemic - expansion of total body water. 
Hypovolemic - Sodium depletion in excess of water depletion. 
Euvolemic - Sodium and water depletion in equal amounts. 
 
II. HYPOVOLEMIC HYPONATREMIA  
A. Primary Na+ loss (secondary water gain) 
1. Integumentary loss : sweating, burns 
2. Gastrointestinal loss : vomiting, tube drainage, fistula, obstruction, diarrhea. 
3. Renal loss : diuretics, osmotic diuresis, hypoaldosteronism, salt wasting    
nephropathy, postobstructive diuresis, nonoliguric acute tubular necrosis 
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B. Primary water gain( secondary Na+ loss) 
1. Primary polydipsia 
2. Decreased solute intake (eg, beer potomania) 
3. AVP release due to pain, nausea, drugs 
4. Syndrome of inappropriate AVP secretion 
5. Glucocorticoid deficiency 
6. Hypothyroidism 
7. Chronic renal insufficiency 
C. Primary Na+ gain (exceeded by secondary water gain) 
1. Heart failure 
2. Hepatic cirrhosis 
3. Nephrotic syndrome 
III. DILUTIONAL OR HYPERVOLUMIC 
Caused by defect in water excretion. 
Sodium-retaining (edematous) states. 
CHF 
Renal failure and nephrotic syndrome. 
Cirrhosis and ascites. 
DIAGNOSIS 
Clinical situation and underlying disease are key to cause. 
Urine sodium concentration usually very low( <10mEq/L). however, with 
acute and chronic renal failure, may have urine Na and Cl concentrations > 
20mEq/L. 
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IV. EUVOLEMIC HYPONATREMIA 
Causes : SIADH. May also be caused by water intoxication but usually 
requires intake of > 10 L/day, hypothyroidism, stress, adrenal insufficiency with a  
urine Na >20 mEq/L. Clinical presentation of Hyponatremia depends on severity 
and time course of disease. 
SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE 
SECRETION 
GI loss such as vomiting, NG suction, Third space losses as with surgery 
excessive    sweating. Renal and adrenal disease including uncontrolled Diabetes 
Mellitus, Hypoaldosteronism, Addison's disease, recovery phase of renal disease, 
etc. 
 
 
V. DRUGS ASSOCIATED WITH HYPONATREMIA 
Increased ADH secretion 
Hypnotics   : barbiturates 
Narcotics   : morphine 
Hypoglycemics  : chlorpropamide, tolutamide 
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Antineoplastics  : vincristine, vinblastine, cyclophosphamide 
Anticonvulsants  : carbamazepine 
Miscellaneous  : clofibrate. isoprenaline, nicotine derivatives. 
Potentiation of ADH secretion 
Chlorpropamide 
Prozac 
Paracetamol 
Indomethacin 
Diuretics 
Thiazides 
Frusemide 
Potassium - sparing: Spironolactone, amiloride, triamterene. 
Consequences of Hyponatremia 
The danger in hyponatremia (hypotonicity) is expansion of the brain cell 
volume (cerebral oedema) and “increased intracranial pressure” due to osmotic 
shifts of water from the ECF. The severity of the clinical syndrome depends on the 
degree and rate of development of the hyponatremia. Symptoms usually do not 
occur until the plasma (Na+) falls to below 120 mmol/l. These are nonspecific and 
include headache, agitation, disorientation, apathy, lethargy, nausea and vomiting. 
When the plasma [Na] falls to below 110 mmoL convulsions, coma, and 
pseudobulbar palsy may occur. 
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HYPONATREMIA IN CIRRHOSIS 
Hyponatremia is commonly found in patients with ascites secondary to 
advanced cirrhosis and portal hypertension. The cause is multifactorial. The 
activation of sodium retaining neuro-hormonal mechanisms like renin angiotensin 
aldosterone system, sympathetic nervous system and antidiuretic hormone due to 
portal hypertension and splanchnic vasodilatation. Also there is “non osmotic 
secretion of ADH” which further worsens excess water retention and hereby 
hyponatremia. (29) 
PATHOGENESIS 
The following mechanisms are attributed to the development of 
hyponatremia in cirrhosis –  
 Systemic vasodilation 
 Release of antidiuretic hormone 
 Non osmotic stimulation of RAAS 
 Sympathetic nervous system                                                                          
SYSTEMIC VASODILATION 
  Systemic vasodilation and underfilling of arteries plays a major role in the 
development of hyponatremia. Cirrhosis leads to a hyperdynamic circulation. The 
marked reduction in vascular resistance, more pronounced in the splanchnic arterial 
circulation, mediated by release of NO and other vasoactive peptides. 
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This splanchnic vasodilation leads to arterial underfilling and the network 
of neurohumoral events resulting in sodium retention. 
ANTIDIURETIC HORMONE 
 Under physiologic conditions, whenever the osmolality increase, AVP 
increases which activates the aquaporin channels in the renal collecting duct that 
leads to increase in free water reabsorption. AVP is a polypeptide hormone 
synthesised in the supraoptic and paraventricular nuclei of the hypothalamus and 
stored in the posterior pituitary gland. Both osmotic and non-osmotic stimulations 
regulate ADH release. Decreased effective circulatory volume in cirrhosis leads to 
non osmotic release of AVP that increases free water reabsorption and precipitates 
dilutional hyponatremia in cirrhosis. 
Decreased effective arterial blood volume also activates RAAS which leads 
to angiotensin mediated salt and water reabsorption. Activation of sympathetic 
nervous system leads to systemic vasoconstriction and decreased gfr. 
     Many other factors including elevated atrial natriuretic peptide , decreased 
renal production of PGE2 and decreased metabolism of ADH has been implicated 
in the development of hyponatremia in cirrhosis. (30) 
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PROGNOSTIC VALUE OF HYPONATREMIA IN CIRRHOSIS 
For several decades now, the severity of cirrhosis has been scored using the 
Child–Pugh system . Use of this score became widespread because of its simplicity 
and its good correlation with long-term outcome in cirrhotic patients. “The Mayo 
End-stage Liver Disease score (MELD)” was initially employed to determine the 
prognosis of cirrhotic patients treated by means of a transjugular portacaval shunt 
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(TIPS). This more recent score comprises three variables: bilirubin levels, INR and 
creatinine levels. However, the latter variable is not included in the Child–Pugh 
scoring system. MELD is a quantitative tool with scores ranging from 6 to 40, a 
maximum score being indicative of the most severe stage. The popularity of this 
more recent score has arisen firstly, from its linear correlation with a quantitative 
value and a risk of death within 3 months, and secondly because of the decision by 
the US health authorities in 2002 to allocate liver grafts as a function of cirrhosis 
severity. This new system of allocating grafts to more severe patients evaluated 
using the MELD score resulted in a dramatic decrease in waiting list mortality 
without significantly impairing post-transplant outcome. It has also resulted in a 
reduction in the number of less severely affected patients being placed on the 
transplant waiting list. In addition, it has been suggested that patients in the US with 
a MELD score lower than 15 have a greater risk of death at one year as a result of 
the transplant procedure itself rather than not undergoing transplantation, 
suggesting that these patients should not be put on the waiting list. The problem 
with this affirmation is that it only takes survival at one year and no further into 
account. Thus most countries have now decided to apply a similar system for graft 
allocation; this is based on the MELD score or on a composite score that includes 
the MELD.  
Unfortunately, this graft allocation system has several major drawbacks: it 
only applies to patients with cirrhosis; those with hepatocellular carcinoma on 
compensated cirrhosis, sclerosing cholangitis, metabolic disease or various other 
rare conditions that are not classified accurately by the MELD score and their access 
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to liver transplantation is problematic. For this reason, an artificial MELD score 
was developed for HCC patients, taking into account the risk of drop out from the 
waiting list by these patients. For other patients, such as those with metabolic 
disease, refractory ascites or recurrent encephalopathy despite a low MELD score, 
the only means of ensuring their access to transplantation was to request their 
prioritization by an expert committee. Returning to cirrhotic patients, several 
authors raised the point that “the Child–Pugh score also takes account of the 
presence of ascites, low albumin levels and encephalopathy, and that these three 
features are absent from the MELD score.” 
On the other hand, the MELD score does not include ascites in the model. 
Ascites itself is a strong factor associated with mortality in cirrhotic patients. 
Among cirrhotic patients who have developed ascites, approximately one-half will 
die in 2 yr. In order to improve the accuracy of the MELD score, investigators have 
looked into other potential prognostic markers. Serum sodium is another common 
laboratory test that is objective and reproducible. It is associated with ascites and 
hepatorenal syndrome, both being predictors of high mortality. Hyponatremia was 
also shown to be an independent factor associated with liver-related mortality 
.looked into other potential prognostic markers Because the volume of ascites is a 
subjective sign, it was suggested that Na values should be added to the MELD score 
in order to allow for the presence of refractory ascites or hepatorenal syndrome 
(HRS). Indeed, hyponatremia is associated with a higher risk of complications with 
ascites and the onset of HRS.  
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In view of these arguments, Kim et al. analyzed the prognostic value of 
hyponatremia at levels between 125 and 140 Meq/l. They built a model that 
considered the prognostic value of both hyponatremia and MELD, and developed 
a new scoring system called MELD–Na. Calculation of this score was based on data 
concerning patients placed on the US waiting list in 2005, as follows: “MELD–Na 
= MELD –Na - [0.025  - MELD - (140 - Na)] +140.” They then applied this new 
score to the cohort of cirrhotic patients placed on the US liver transplant waiting 
list in 2006. They showed that MELD and hyponatremia were correlated with the 
mortality risk, and also demonstrated that the MELD–Na score was more predictive 
of the risk of death in more severe patients, and particularly those with a MELD 
score of between 20 and 39. The presence of hyponatremia thus adds points to the 
current MELD score, so that a patient with hyponatremia will have a higher 
MELD–Na score than the same patient with normal serum sodium levels. As a 
result, refractory ascites has recovered indirectly its importance to scoring, as 
suggested by the Child–Pugh score. (31-33) 
This new score needs to be validated in additional independent cohorts, and 
it will be interesting to determine whether it will benefit the more severely affected 
patients only, or the entire cohort of cirrhotic patients.  
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MELD Na = MELD − Na − [0.025 × MELD × (140 − Na)] + 140 
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Hence, addition of serum sodium into the MELD score will put the 
patient into high scores which will predict his mortality much better than the 
MELD score alone. This will increase the likelihood of that patient getting liver 
transplant earlier than that predicted by MELD score. (34-38) 
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MATERIALS AND METHODS 
STUDY POPULATION: 
SOURCE OF DATA: 
            The study will be conducted on 100 patients admitted to Government 
Rajaji Hospital & Madurai Medical College during the study period from June 
2017 to September 2017. 
Inclusion criteria: 
All patients with cirrhosis of liver. 
Exclusion criteria: 
1. Patients with cardiac failure 
2. Patient on diuretic therapy. 
3. Patients with chronic kidney disease  
4. Patients on drugs like SSRI, TCA, MAO inhibitors, cytotoxic drugs etc. 
5. Pregnancy, Hypothyroidism, Diabetes mellitus 
PARTICIPANTS:  
100 liver cirrhosis patients at Department of medicine and Department of 
Medical gastroenterology, Government Rajaji hospital, Madurai. 
DESIGN OF STUDY: 
Prospective study. 
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PERIOD OF STUDY: 
4 MONTHS (June 2017 to September 2017) 
DATA COLLECTION: 
Informed consent will be obtained from all patients to be enrolled for the 
study. In all the patients relevant information will be collected in a predesigned 
Proforma. 
METHODOLOGY: 
• History was taken on details and duration of alcoholism, jaundice, ascites, 
oliguria, pedal edema and gastrointestinal bleed. Presence or absence of 
jaundice, ascites, splenomegaly and hepatic encephalopathy was noted. 
Platelet count, prothrombin time and INR, liver function tests including 
serum bilirubin, serum transaminases, serum albumin was estimated. Based 
upon the serum sodium values, patients are divided into three groups. 
                                 Group 1 - Sr sodium > 135 
                                 Group 2 – Sr sodium 131 - 135 
                                 Group 3 – Sr sodium <130 
• The presence of following baseline characteristics of patients were 
recorded at admission – 
                        Ascites 
                        Variceal bleed 
             Hepatic encephalopathy 
                      Spontaneous bacterial peritonitis 
                      Hepatorenal syndrome 
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The presence of complications and its frequency in all 3 groups were 
studied and analysed. An ultrasonogram abdomen and Doppler study of portal 
venous system, the portal vein and spleen diameter along with echo texture of 
the liver, spleen size and direction of blood flow, ascites was noted. MELD 
score and MELD - Na are calculated for each patient and compared. Patients 
are followed up for a period of three months for complications and the short 
term mortality. 
LABORATORY INVESTIGATIONS 
a) Complete blood count, 
b) Renal function test, 
c) Liver function test, 
d) Urine routine, 
e) Serum electrolyte, 
f) HBsAg, 
g) HCV, 
h) Prothrombin time, aPTT and INR 
i) Electrocardiogram, 
j) Echo  
k) Chest X ray, 
l) USG abdomen 
m)      FBS,PPBS  
n)       Thyroid function test 
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COLLABORATING DEPARTMENTS: 
DEPARTMENT OF MEDICAL GASTROENTEROLOGY 
DEPARTMENT OF BIOCHEMISTRY 
DEPARTMENT OF RADIOLOGY 
ETHICAL CLEARANCE: Clearance obtained 
CONSENT: Individual written and informed consent. 
ANALYSIS: All data were entered in Excel 2007 and statistical analysis was 
performed using the statistical software SPSS 16.0.Data were expressed as 
frequency (with percentages), median values (with range (min, max)). For 
continuous variables, Mann Whitney U-test was performed to find the 
differences between two groups and for categorical variables Pearson’s chi-
square test was performed. Results were defined as statistically significant when 
the P value (2-sided) was less than 0.05. 
CONFLICT OF INTEREST: NIL 
FINANCIAL SUPPORT:  SELF                                          
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RESULTS AND OBSERVATIONS 
 
TABLE 1 - DISTRIBUTION OF HYPONATREMIA 
 
 
COMMENTS 
Out of 100 patients, 40 were found to have sr. sodium more than 135, 32 
were found to have sr. sodium between 130 and 135 and 28 patients had sr sodium 
below 130meq/L. 
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No. of patients
Sr. SODIUM 
GROUP A 
(>135) 
GROUP B 
(130-135) 
GROUP C 
(<130) 
PATIENTS 40 32 28 
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Table 2: DISTRIBUTION OF AGE 
COMMENTS 
The mean age of patients in Groups A, B and C are 46yrs, 46 yrs and 48 yrs 
respectively. No statistically significant difference was found between the three 
groups with respect to age. 
46.97 46.78
48.43
40
42
44
46
48
50
Group A Group B Group C
COMPARISON OF MEAN AGE 
Mean
AGE Group A Group B Group C 
Mean 46.97 46.78 48.43 
SD 8.45 8.17 6.94 
 p value 0.684  Not Significant 
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Table 3 – DISTRIBUTION OF GENDER 
Gender Group A Group B Group C 
Male 28 24 20 
Female 12 8 8 
 p value 0.893   Not Significant 
COMMENTS 
In group A, 28 patients were male and 12 patients were female. In group B, 
24 patients were male and 8 patients were female. In group C, 20 patients were male 
and 8 patients were females. . No statistically significant difference was found 
between the three groups with respect to gender. 
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Table 3 – DISTRIBUTION OF ETIOLOGY 
 
COMMENTS 
Alcohol was the most common cause of cirrhosis in all the three groups 
(48%). Other cyptogenic causes predominate next to alcohol which was followed 
by chronic Hepatitis B, Chronic Hepatitis C, combined alcohol and chronic 
Hepatitis B, combined alcohol and chronic Hepatitis C and at last by Wilson’s 
disease. 
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Al +
HCV
HBV HCV Others Wilson
COMPARISON OF ETIOLOGY
Group A Group B Group C
Etiology Group A Group B Group C 
Alcohol 21 14 13 
Alcohol + HBV 0 1 2 
Alcohol + HCV 0 0 2 
HBV 3 6 4 
HCV 3 4 2 
Others 12 7 5 
Wilson 1 0 0 
Total 40 32 28 
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Table 4 – DISTRIBUTION OF ASCITES 
Ascites Group A Group B Group C 
Nil 23 6 0 
Present 17 26 28 
 p value <0.001 Significant 
 
COMMENTS 
In group A, 17 patients (42.5%) had ascites and in group B, 26 patients 
(81.25%) had ascites. In group C, 28 patients (100%) had ascites. As the p value is 
<0.001 Significant, presence of hyponatremia is a significant predictor of ascites in 
cirrhosis patients. There was a significant difference in ascites in group C compared 
to groups A and B. The same was true of group B compared to group A.  
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54 
Table 5 – DISTRIBUTION OF HEPATIC ENCEPHALOPATHY 
H.E Group A Group B Group C 
Nil 38 32 10 
Present 2 8 18 
 p value <0.001 Significant 
COMMENTS 
In group A, 2 patients (5%) had hepatic encephalopathy and in group B, 8 
patients (25%) had hepatic encephalopathy. In group C, 18 patients (64.21%) had 
hepatic encephalopathy. As the p value is <0.001 Significant, presence of 
hyponatremia is a significant risk factor for the development of hepatic 
encephalopathy in cirrhosis patients. There was a significant difference in hepatic 
encephalopathy in group C compared to groups A and B. The same was true of 
group B compared to group A. 
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Table 6 – DISTRIBUTION OF HEPATORENAL SYNDROME 
HRS Group A Group B Group C 
Nil 37 25 17 
Present 3 7 11 
 p value 0.007  Significant 
 
COMMENTS 
In group A, 3 patients (7.5%) had hepatorenal syndrome and in group B, 7 
patients (21.8%) had hepatorenal syndrome. In group C, 11 patients (39.28%) had 
hepatorenal syndrome. As the p value is <0.007 Significant, development of 
hepatorenal syndrome in cirrhosis patients is significantly associated with 
hyponatremia.  
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Table 7 – DISTRIBUTION OF SPONTANEOUS BACTERIAL PERITONITIS 
SBP Group A Group B Group C 
Nil 36 22 14 
Present 4 10 14 
 p value 0.001 Significant 
COMMENTS 
In group A, 4 patients (10%) had SBP and in group B, 10 patients (31.25%) 
had SBP. In group C, 14 patients (50%) had SBP. As the p value is <0.001 
Significant, development of SBP in cirrhosis patients is significantly associated 
with hyponatremia. 
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Table 8 – DISTRIBUTION OF VARICEAL BLEED 
Variceal blood Group A Group B Group C 
Nil 36 26 16 
Present 4 6 12 
 p value 0.005  Significant 
 
COMMENTS 
In group A, 4 patients (10%) had variceal bleed and in group B, 6 patients 
(38.75%) had variceal bleed. In group C, 12 patients (42.85%) had variceal bleed. 
As the p value is 0.005 Significant, development of variceal bleed in cirrhosis 
patients is significantly associated with hyponatremia.  
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MELD Vs MELD Na 
MELD Group A Group B Group C 
Mean 19.15 21.5 23.28 
SD 2.48 4.57 7.25 
 p value  0.001  Significant 
 
 
 
COMMENTS 
The MELD and MELD-Na scores increased significantly in group C 
compared to groups A and B and in group B compared to group A. When compared 
to MELD score, the differences between the 3 groups was highly significant in 
MELD Na scores. 
      The MELD Na scores showed significant difference between scores 29 to 
39 which reflect the presence of hyponatremia.  
MELD Na Group A Group B Group C 
Mean 14.07 23.22 28.89 
SD 2.67 3.87 4.97 
 p value < 0.001  Highly Significant 
Mean  Group A Group B Group C 
Meld 19.15 21.5 23.28 
Meld Na 14.07 23.22 28.89 
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SHORT TERM MORTALITY (AT 3 MONTHS) 
Status at 3 months Group A Group B Group C 
Alive 40 31 19 
Death 0 1 9 
 p value < 0.001  Significant 
 
 
COMMENTS 
At the end of 3 months of registration, patient’s status was reviewed. 10 
patients were died. In group B, 1 patient died and in group C, 9 patients died (8 
males and 1 Female). As the p value is <0.001 Significant, presence of 
hyponatremia is a significant risk factor for the mortality in cirrhosis patients. There 
was a significant increased mortality in group C compared to groups A and B. No 
patient with MELD-Na scores below 10 died during the study. The MELD-Na score 
correlated strongly with short term in-hospital mortality.  
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10 20.7 27.2 
P value Significant < 0.001 
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PATIENT MELD MELD Na 
Predicted 
mortality at 3 
months with 
MELD 
Predicted 
mortality at 3 
months with 
MELD Na 
1 27 30 19.6 % 52.6 % 
2 16 25 6.0 % 19.6 % 
3 27 31 19.6 % 52.6 % 
4 17 25 6.0 % 19.6 % 
5 14 23 6.0 % 19.6 % 
6 16 23 6.0 % 19.6 % 
7 15 24 6.0 % 19.6 % 
8 17 25 6.0 % 19.6 % 
9 18 26 6.0 % 19.6 % 
10 40 40 71.3% 71.3% 
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Although this may be a modest number, the use of the MELD Na score could 
be an important improvement in identifying a subgroup of patients with cirrhosis 
who have severe fluid retention and a high risk of death. In this study, as compared 
with the MELD score, the MELD Na score provides better calibration and 
discrimination of the risk of death among candidates for liver transplantation; thus, 
use of the MELD Na score may reduce mortality among patients on the waiting list. 
Since the MELD Na score differs substantially from the MELD score only for 
patients with hyponatremia, the proportion of candidates for Liver transplantation 
who would be affected by the use of this combined score would be modest. Among 
such patients, however, the magnitude of the difference between the MELD score 
and the MELD Na score was often large enough to make a real difference in the 
probability of receiving a liver transplant and averting death. 
DISCUSSION 
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DISCUSSION 
Out of 100 patients, 40 were found to have sr. sodium more than 135, 32 
were found to have sr. sodium between 130 and 135 and 28 patients had sr sodium 
below 130meq/L.The mean age of patients in Groups A, B and C are 46yrs, 46 yrs 
and 48 yrs respectively. No statistically significant difference was found between 
the three groups with respect to age. In group A, 28 patients were male and 12 
patients were female. In group B, 24 patients were male and 8 patients were female. 
In group C, 20 patients were male and 8 patients were females. . No statistically 
significant difference was found between the three groups with respect to gender. 
Alcohol was the most common cause of cirrhosis in all the three groups 
(48%). Other cryptogenic causes predominate next to alcohol which was followed 
by chronic Hepatitis B, Chronic Hepatitis C, combined alcohol and chronic 
Hepatitis B, combined alcohol and chronic Hepatitis C and at last by Wilson’s 
disease. In group A, 17 patients (42.5%) had ascites and in group B, 26 patients 
(81.25%) had ascites. In group C, 28 patients (100%) had ascites. As the p value is 
<0.001 Significant, presence of hyponatremia is a significant predictor of ascites in 
cirrhosis patients. There was a significant difference in ascites in group C compared 
to groups A and B. The same was true of group B compared to group A. 
In group A, 2 patients (5%) had hepatic encephalopathy and in group B, 8 
patients (25%) had hepatic encephalopathy. In group C, 18 patients (64.21%) had 
hepatic encephalopathy. As the p value is <0.001 Significant, presence of 
hyponatremia is a significant risk factor for the development of hepatic 
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encephalopathy in cirrhosis patients. There was a significant difference in hepatic 
encephalopathy in group C compared to groups A and B. The same was true of 
group B compared to group A. 
In group A, 3 patients (7.5%) had hepatorenal syndrome and in group B, 7 
patients (21.8%) had hepatorenal syndrome. In group C, 11 patients (39.28%) had 
hepatorenal syndrome. As the p value is <0.007 Significant, development of 
hepatorenal syndrome in cirrhosis patients is significantly associated with 
hyponatremia. In group A, 4 patients (10%) had SBP and in group B, 10 patients 
(31.25%) had SBP. In group C, 14 patients (50%) had SBP. As the p value is <0.001 
Significant, development of SBP in cirrhosis patients is significantly associated 
with hyponatremia. In group A, 4 patients (10%) had variceal bleed and in group 
B, 6 patients (38.75%) had variceal bleed. In group C, 12 patients (42.85%) had 
variceal bleed. As the p value is 0.005 Significant, development of variceal bleed 
in cirrhosis patients is significantly associated with hyponatremia. 
The MELD and MELD-Na scores increased significantly in group C 
compared to groups A and B and in group B compared to group A. When compared 
to MELD score, the differences between the 3 groups was highly significant in 
MELD Na scores. The MELD Na scores showed significant difference between 
scores 29 to 39 which reflect the presence of hyponatremia. At the end of 3 months 
of registration, patient’s status was reviewed. 10 patients were died. In group B, 1 
patient died and in group C, 9 patients died (8 males and 1 Female). As the p value 
is <0.001 Significant, presence of hyponatremia is a significant risk factor for the 
mortality in cirrhosis patients. There was a significant increase in mortality in group 
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C compared to groups A and B. No patient with MELD-Na scores below 10 died 
during the study. The MELD-Na score correlated strongly with short term in-
hospital mortality. 
Several previous research work has been done in signifying the role of 
hyponatremia and incorporating sodium into standard MELD scores. In this study, 
we found that hyponatremia is associated with increased risk of complications 
(encephalopathy, renal injury, SBP, GIT bleeding, degree of ascites) in patients 
with decompensated cirrhosis. This was in accordance with the study of Paolo 
Angeli et al. who observed that low serum sodium levels in cirrhosis are associated 
with severe ascites and high frequency of hepatic encephalopathy, spontaneous 
bacterial peritonitis, and hepatorenal syndrome.  Ashraf Abd El-Khalik Barakat et 
al. observed that in cirrhosis, hyponatremia is more common and associated with 
increased risk of hepatic encephalopathy, ascites, illness severity scores, renal 
failure, infectious complications, and pleural effusion. W. Ray Kim et al. showed 
that the MELD score and the serum sodium concentration are important predictors 
of survival among candidates for liver transplantation. 
The results of this study confirms the association between hyponatremia and 
mortality in patients with end-stage liver disease. 
CONCLUSION 
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CONCLUSION 
The importance of the findings of this study emphases on the significant 
negative effect of hyponatremia on the short-term survival of patient with cirrhosis 
in liver transplant waiting list. Using serum sodium as a variable and incorporating 
it into the MELD score further increased the accuracy of the prediction model. The 
existence of serum sodium concentration <135 mmol/L is associated with a poor 
control of ascites and greater frequency of hepatic encephalopathy, hepatorenal 
syndrome, and spontaneous bacterial peritonitis compared with patients with serum 
sodium concentration within the normal range (>135 mmol/L). Hyponatremia and 
ascites were the only 2 independent factors associated with mortality when the 
MELD score was below 21. In our study, though patients with ascites had lower 
serum sodium, hyponatremia remained an independent predictor of mortality. The 
majority of our patients had baseline MELD score below 21. In keeping with other 
studies in Western countries, incorporating serum sodium or ascites variables into 
the MELD score improved the power to predict short term mortality. The 
observation in this study that MELD based scores incorporating sodium are better 
predictors of death on the waiting list for Liver Transplantation than MELD alone 
, confirms Sr Na as a robust predictor of waiting list mortality. 
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LIST OF ABBREVIATION 
LFT - liver function test 
AST - Aspartate aminotransferase 
ALT - Alanine aminotransferase 
UGI - Upper Gastrointestinal 
MELD - Model for End stage Liver Disease score 
CTP - child turcotte pugh 
PT - prothrombin time 
TIPSS - Transjugular Intrahepatic Portosytemic Shunt Surgery 
NO - Nitric Oxide 
GV - gastric varices 
EVL - endoscopic variceal ligation 
EGD - esophago gastroduodenoscopy 
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PROFORMA 
Name:  Age / Sex: 
IP no: 
Occupation: 
Presenting complaints: 
h/o, jaundice, ascites, oliguria, pedal edema , gastrointestinal bleed, altered 
sensorium. 
Past History: 
h/o Jaundice, blood transfusion, tattoing, iv drug use, sexual promiscuity 
h/o CLD, DM, HT, CKD, CVD, DRUG INTAKE, THYROID 
DISORDERS,EPILEPSY,HEPATITIS. 
Personal history 
alcoholic/ non alcoholic 
smoker/ nonsmoker 
General Examination: 
Consciousness, orientation, febrile/afebrile, Pallor, jaundice, Clubbing, 
Lymphadenopathy, pedal edema. 
Vitals: 
PR 
BP 
RR 
SpO2 
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Systemic examination: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
LABORATORY INVESTIGATIONS 
Hb Tb Sr. Alb Anti HCV 
RBC DB PT Sr. Urea 
TC IDB APTT Creatinine 
DC SGOT INR Na 
PLT SGPT HBSAg K 
ECG FBS 
CXR PPBS 
ECHO URINE 
R/E 
TFT 
USG Abdomen: 
Liver : 
Portal Vein  : 
Spleen : 
Others  : 
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Scores 
1). MELD : 
2). MELD – Na : 
 Status 3 Months after registration:       Death / Alive 
MASTER CHART 
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MASTER CHART 
S.N NAME GP AGE SEX ETIOLOGY AS H.E HRS SBP V.B T.B INR Cr Na+ MELD 
MELD 
Na 
STATUS 
1 VIJAYAKUMAR C 40 M alcohol -  -  -  -  - 1.66 1.36 1 140 12 12 Alive 
2 BALARAMAN C 43 M alcohol P  -  - P P 1.72 1.5 1 137 13 15 Alive 
3 NARASIMHAN C 52 M HCV  -  -  -  -  - 1.5 1.1 1.4 137 15 17 Alive 
4 MUNIYAMMAL B 44 F HBV P  - P  -  - 3.1 1.9 1.8 131 24 27 Alive 
5 RAJENDRAN A 49 M alcohol P P P  - P 8.8 3.12 4.1 128 40 40 DEATH 
6 ELUMALAI A 42 M alc+HCV P P P  -  - 6.3 1.1 1.2 126 16 25 DEATH 
7 PANDIARAJAN C 46 M alcohol  -  -  -  -  - 1.53 1.7 1 137 14 16 Alive 
8 PONNUTHAI A 38 F HCV P P P P  - 14.2 2.56 1.9 124 33 36 Alive 
9 BENJAMIN C 40 M alcohol  -  -  -  -  - 1.62 1.15 1.05 142 10 10 Alive 
10 ALEXANDER B 40 M others P  - P P  - 4.2 2.1 2 131 27 30 Alive 
11 RAJESHWARI B 38 F others P  -  - P  - 2 1.1 1 134 10 15 Alive 
12 KARTHIKA C 34 F Wilsons P  -  -  -  - 1.56 1.1 1 137 9 9 Alive 
13 SUDHARRANAM A 61 M alcohol  - P  -  - P 5.3 2.01 1.1 130 21 28 Alive 
14 SAMY B 47 M alcohol P  - P P  - 2.8 1.5 1.7 131 20 24 Alive 
15 LAKSHMI A 46 F others P  -  -  -  - 6.3 1.65 1.3 129 22 27 Alive 
16 VETRIVEL C 52 M HBV P  -  - P  - 1.83 1.6 1.4 137 17 19 Alive 
17 RANGANADHAN A 55 M alcohol P P P  - P 9.5 1.52 2.1 126 27 31 DEATH 
18 RAVICHANDRAN B 39 M others P  - P  -  - 3.9 1.7 1.7 134 29 22 Alive 
19 SHAKUNTHALA C 38 F HBV  -  -  -  -  - 1.89 1.33 1.2 136 14 16 Alive 
20 JEYAKUMAR B 46 M alcohol P  - P  -  - 4 1.8 1.9 131 24 28 DEATH 
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21 SEKAR BABU A 41 M alcohol P P  - P  - 4.9 1.39 1.1 128 17 24 Alive 
22 GOMATHI B 52 F HCV P  -  -  -  - 3.1 2 1.3 135 21 23 Alive 
23 ANBAZHAGAN C 51 M others P P  -  -  - 1.9 1.45 1.2 139 15 15 Alive 
24 MOHAN C 43 M alcohol  -  -  -  -  - 1.26 1.4 1 140 11 11 Alive 
25 SUBRAMANIAN A 50 M alcohol P P  -  - P 4.1 1.2 1.4 126 17 25 DEATH 
26 NATARAJ B 48 M others P  -  -  - P 4.2 1.9 1.4 133 22 25 Alive 
27 ARVIND C 37 M alcohol P  - P  -  - 1.88 1.2 2.2 138 18 19 Alive 
28 ALAGU A 44 F HBV P  -  -  -  - 5.4 2.01 1.4 130 24 28 Alive 
29 KOTHANDAPANI C 38 M alcohol  -  -  -  -  - 2.05 1.5 1.1 139 15 16 Alive 
30 ANBARASAN B 40 M alcohol P  -  -  -  - 3.5 2.1 0.9 135 19 22 Alive 
31 KARUNANITHI B 41 M alcohol P  - P P  - 3.4 1.9 2.1 131 25 29 DEATH 
32 RAJA B 49 M alcohol P  -  -  -  - 3.8 1.9 0.9 134 19 22 Alive 
33 KARUPPAYE A 50 F others P P  -  -  - 4 2.06 1.4 127 23 29 Alive 
34 SUNDAR C 36 M HBV P  -  - P  - 2.12 1.3 1 136 12 15 Alive 
35 PALANI A 38 M alcohol P P  - P P 5.3 1.5 1 127 17 25 Alive 
36 PUGAZHENTHI C 44 M alcohol  -  -  -  -  - 1.36 1 1.1 137 9 11 Alive 
37 VELAMMAL B 40 F HCV P  -  -  -  - 3.8 1.9 1.1 132 17 21 Alive 
38 ARASU C 45 M others  -  -  -  -  - 1.54 1.24 1.3 141 13 13 Alive 
39 RAVI A 47 M HCV P P P P  - 6.2 1.1 3.3 127 26 30 Alive 
40 PARTHIBAN B 52 M alcohol P  -  -  -  - 3.3 1.9 0.9 134 18 21 Alive 
41 DURAIMURUGAN B 68 M alcohol P  -  - P P 4.5 2.4 1.2 131 24 27 DEATH 
42 VEERAYI A 43 F HBV P  -  -  - P 5.4 2.16 1.3 130 24 28 Alive 
43 GANDHI C 44 M alcohol P P  -  -  - 1.68 1.1 1 137 9 12 Alive 
44 RATHAMANI B 49 F HBV  -  -  -  -  - 3.3 1.7 1.3 132 19 24 Alive 
45 ESWARAPPAN A 66 M alc+hbv P P P P  - 15.5 2.92 2.2 125 36 38 DEATH 
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46 KARTHIKEYAN C 50 M others  -  - P  - P 1.35 1.28 2 139 17 18 Alive 
47 GOVINDAMMAL C 50 F others P  -  -  -  - 1.8 1.36 1 137 12 14 Alive 
48 NANDAKUMAR B 46 M HBV P  -  - P  - 2.9 1.6 1.2 133 17 21 Alive 
49 LOGANATHAN A 44 M alcohol P  -  - P P 10.8 2.33 1.5 128 27 31 Alive 
50 SIVAKUMAR C 43 M alcohol  -  -  -  -  - 1.46 1.5 1.3 138 16 16 Alive 
51 SAROJA A 60 F others p  -  -  -  - 4.1 2.33 1.2 130 23 27 Alive 
52 VEERAMANI A 47 M alcohol p p  - p  - 6.1 1 1.1 126 14 23 DEATH 
53 NALLATHAMBI C 45 M alcohol p  -  -  - p 1.86 1.74 1 140 15 15 Alive 
54 RAJENDRAN B 36 M HCV p  -  -  -  - 3 1.9 0.9 133 18 22 Alive 
55 SENGUTTAVAN B 39 M alcohol p  - p  - p 3.6 2.8 1.7 132 27 30 DEATH 
56 VALARMATHI C 36 F others p  -  -  -  - 1.77 1.2 1 142 11 11 Alive 
57 MURUGAN A 42 M alc+hbv p  -  - p p 8.6 1.22 1.5 128 26 30 Alive 
58 PALANIYAPPAN C 40 M alcohol  -  -  -  -  - 1.84 1.7 0.9 137 15 17 Alive 
59 TAMILSELVI C 65 F others p  -  -  -  - 1.9 1.3 1.2 138 14 15 Alive 
60 RAMACHANDRAN B 60 M alcohol p  -  -  -  - 3 1.9 1.5 133 22 25 Alive 
61 MOHAN B 39 M HBV P  -  -  - P 3.1 1 1.4 131 14 20 Alive 
62 MASTHAN A 52 M alcohol P P P  - P 12.8 2.14 2.7 127 34 36 Alive 
63 CHINNAMMAL C 46 F others  -  -  -  -  - 1.6 1 1.2 137 10 12 Alive 
64 SEETHAPATHY B 49 M alcohol  -  -  -  -  - 2.6 1.6 1.1 133 16 20 Alive 
65 CHAKRAPANI A 51 M alcohol P P  -  - P 4.6 1.42 1 129 16 23 DEATH 
66 KUMARAGURU C 39 M alcohol P  -  -  -  - 1.75 1.1 0.9 138 10 11 Alive 
67 KARTHIKEYAN B 41 M alcohol  -  -  -  -  - 1 1.5 0.9 134 11 15 Alive 
68 POONGOTHAI B 46 F HBV P  -  -  -  - 3.4 2.1 1.5 134 23 26 Alive 
69 UDHAYASURIYAN C 44 M alcohol  -  - P  -  - 1.75 1.1 1.8 140 15 15 Alive 
70 VETRIVEL C 48 M alcohol  -  -  -  -  - 1.69 1 1.6 137 13 15 Alive 
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71 PRINCE C 44 F others  -  -  -  -  - 1.55 1 1.3 136 11 14 Alive 
72 VENKATACHALAM A 40 M HBV p p p p  - 10.8 1.34 2.8 121 29 33 Alive 
73 SAKTHIVEL B 39 M alcohol p  -  - p  - 3.2 1.7 1 133 17 21 Alive 
74 SEENITHAI A 58 F others p p p p  - 8.1 1 1.1 126 15 24 DEATH 
75 KARUPPANAN C 62 M alcohol p  -  -  - p 1.96 1.63 0.9 137 14 16 Alive 
76 DHANAPAL B 60 M others p  -  -  - p 3.7 2 1.4 134 22 25 Alive 
77 MEENAMBAL C 55 F others  -  -  -  -  - 1.67 1.42 0.9 143 12 12 Alive 
78 ARJUNAN B 49 M HCV p  -  - p  - 3.8 0.9 1.1 132 20 24 Alive 
79 PERIYASAMY A 48 M alcohol p p  - p  - 4.2 1.9 0.9 128 19 25 Alive 
80 RASU C 65 M alcohol p  -  -  -  - 1.78 1 0.9 136 9 12 Alive 
81 PARAMASHIVAN B 62 M HBV P  -  - P  - 4.2 2.2 1.1 131 22 26 Alive 
82 PAUNTHAI C 60 F others  -  -  -  -  - 1 1.5 0.9 137 12 14 Alive 
83 JEGANATHAN A 49 M alcohol P  -  - P P 3.2 1.5 1.2 127 17 25 DEATH 
84 RAMU C 65 M alcohol P  -  -  -  - 1.88 1.2 0.9 138 11 13 Alive 
85 MURUGAMMAL A 52 F others  -  -  -  -  - 3.9 1.2 1.1 128 16 22 Alive 
86 GANESAN C 46 M HCV  -  -  -  -  - 1.83 1.2 1 137 11 14 Alive 
87 SAMPATH C 39 M alcohol  -  -  -  -  - 1.58 1.3 1.2 138 13 14 Alive 
88 SUNDARI B 45 F others  -  -  -  -  - 2.2 1.5 1 134 14 18 Alive 
89 PANEERSELVAM A 49 M alcohol P  - P P  - 6.3 2.2 2.9 126 32 35 Alive 
90 MATHIVANAN C 53 M alcohol P  -  -  -  - 1.3 1.1 0.9 140 8 8 Alive 
91 CHEZHIAN B 43 M alcohol P  -  -  - P 3.9 1.8 1.4 131 21 26 Alive 
92 PARAMESHWARI C 55 F others  -  -  -  -  - 1.46 1.8 1.1 136 15 18 Alive 
93 GOVINDARASU A 50 M HBV P P  - P  - 4.5 1.4 1.3 125 18 26 DEATH 
94 PERIYAKARUPPAN B 49 M alc+hbv  -  -  -  -  - 2 1.3 1.2 133 14 18 Alive 
95 KASTHURI C 51 F others  -  -  -  -  - 1.95 1.22 0.9 141 11 11 Alive 
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96 RAGUPATHY A 44 M alc+hcv P  - P  - P 9.6 1.95 3.1 130 33 35 Alive 
97 MASILAMANI C 40 F HCV  -  -  -  -  - 1.6 1.6 1 136 14 16 Alive 
98 SOORYAKUMAR B 39 M alcohol P  -  - P  - 3.4 2.1 1.5 134 23 26 Alive 
99 VARALAKSHMI B 62 F others  -  -  -  -  - 2.8 1.2 1.4 132 16 20 Alive 
100 PICTHAIYAPPAN C 55 M alcohol P  -  - P  - 2 1.4 1 136 13 16 Alive 
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